Crispr Therapeutics AG (NASDAQ:CRSP) Director Kurt Von Emster sold 92,337 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $26.96, for a total transaction of $2,489,405.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Kurt Von Emster also recently made the following trade(s):
- On Tuesday, January 2nd, Kurt Von Emster sold 37,754 shares of Crispr Therapeutics stock. The shares were sold at an average price of $26.76, for a total transaction of $1,010,297.04.
Shares of Crispr Therapeutics AG (CRSP) traded down $1.57 during trading on Friday, hitting $36.91. 748,954 shares of the stock were exchanged, compared to its average volume of 911,881. Crispr Therapeutics AG has a 52 week low of $11.63 and a 52 week high of $45.00. The company has a market capitalization of $1,620.00 and a PE ratio of -115.34.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The firm had revenue of $2.39 million for the quarter, compared to the consensus estimate of $3.61 million. During the same period in the prior year, the company earned ($2.77) EPS. The company’s revenue for the quarter was up 54.2% compared to the same quarter last year. analysts expect that Crispr Therapeutics AG will post -2.42 EPS for the current fiscal year.
CRSP has been the topic of several research reports. SunTrust Banks upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Piper Jaffray Companies reiterated a “buy” rating and issued a $22.75 price objective (down from $39.00) on shares of Crispr Therapeutics in a report on Wednesday, January 10th. BidaskClub raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. Oppenheimer reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, December 21st. Finally, Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Sunday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Crispr Therapeutics has a consensus rating of “Buy” and an average target price of $22.81.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Global Thematic Partners LLC lifted its position in Crispr Therapeutics by 11.2% during the fourth quarter. Global Thematic Partners LLC now owns 633,452 shares of the company’s stock worth $14,873,000 after purchasing an additional 63,611 shares during the period. Granahan Investment Management Inc. MA lifted its position in Crispr Therapeutics by 51.7% during the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock worth $4,713,000 after purchasing an additional 89,839 shares during the period. Capital Advisors Inc. OK bought a new stake in Crispr Therapeutics during the fourth quarter worth about $3,515,000. Allianz Asset Management GmbH bought a new stake in Crispr Therapeutics during the third quarter worth about $2,384,000. Finally, Adams Street Partners LLC bought a new stake in Crispr Therapeutics during the third quarter worth about $1,019,000. 21.89% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Crispr Therapeutics AG (NASDAQ:CRSP) Director Kurt Von Emster Sells 92,337 Shares” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/03/insider-selling-crispr-therapeutics-ag-crsp-director-sells-2489405-52-in-stock.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.